Study Overview
BAY 2413555 is a new treatment aimed at improving heart function in patients with heart failure (HF). This study focused on its safety, tolerability, and how the body processes it.
Key Details of the Study
- The study was called REMOTE-HF and included multiple centers.
- It was a double-blind, placebo-controlled trial.
- Participants had HF with reduced heart function (LVEF ≤ 45%) and required specific heart devices.
- The study lasted over 28 days, with treatments divided into two phases.
Participants and Treatment Arms
Out of 129 planned participants, 22 were included:
- 7 in the placebo group
- 8 received 1.25 mg of BAY 2413555
- 7 received 1.25 mg for the first part and 5 mg for the second part
Findings
The study was stopped early due to new safety concerns from animal studies, but the preliminary results indicated:
- BAY 2413555 was overall safe and well tolerated.
- No serious side effects or discontinuations occurred.
- There was a notable improvement in heart rate recovery, suggesting enhanced heart function.
Practical Solutions and Value
Clinical trials like this are essential for finding safe and effective treatments. To integrate these findings into everyday practice:
- DocSym is an AI-driven platform that provides access to clinical guidelines and research, making it easier for healthcare providers to stay informed.
- Our mobile apps simplify scheduling and treatment monitoring, enhancing patient care.
- By adopting AI, clinics can improve workflows, reduce paperwork, and support better patient outcomes.
Learn more about how we can assist at aidevmd.com.
